Mode
Text Size
Log in / Sign up
Phase 3 Completed N=419 Treatment

Lubiprostone for Children With Constipation

Constipation - Functional
Source: ClinicalTrials.gov NCT02138136 ↗
Enrolled (actual)
419
Serious AEs
3.1%
Results posted
Jan 2020
Primary outcomePrimary: Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month — 2.66; 2.75; 2.70; 2.75 Weekly SBMs
◆ Published Evidence
Established
51citations · ~13 / year
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Open access · Likely link

Summary

This study is for children with constipation. Children who completed 3 months of treatment in the earlier study (NCT02042183): * were invited to participate * will receive lubiprostone for 9 more months * will see if lubiprostone safely relieves their constipation if taken for a whole year

Linked Publications

  • Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · 51 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Median Number of Observed Weekly Spontaneous Bowel Movements (SBM) Per Month
2.66; 2.75; 2.70; 2.75; 2.74; 2.50

Eligibility Criteria

Inclusion Criteria

  • Has completed the 3-month placebo-controlled study (NCT02042183)
  • Will continue to abstain from taking concomitant medication (prescribed or over-the-counter) that affects gastrointestinal motility

Exclusion Criteria

  • Has untreated faecal impaction at the time of rolling over into study
  • Has significant change in medical status, newly diagnosed and uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other systemic disease
  • Has demonstrated non-compliance with study protocol during the 3-month placebo-controlled study (NCT02042183)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02138136) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search